European Commission Grants Approval for Oral Semaglutide in Weight Management

The European Commission has issued marketing authorization for once-daily oral semaglutide 25 mg tablets, marketed under the Wegovy brand, for the management of obesity and weight-associated comorbidities in adults.

This regulatory milestone marks the introduction of the first GLP-1 receptor agonist in oral form for weight management within the European Union, extending the drug’s existing presence in the United States, the United Kingdom, the United Arab Emirates, and Bahrain.

Regulatory Approval Details

Under the new European authorization, the oral 25 mg tablet is indicated for adults with a Body Mass Index (BMI) of 30 kg/m² or higher, or those with a BMI of 27 kg/m² or higher who present with at least one weight-related condition.

The approval is based on findings from the phase 3 OASIS clinical trial program, which evaluated both 25 mg and 50 mg daily doses across a cohort of approximately 1,300 adults.

Clinical data from the 64-week OASIS 4 study, involving 307 participants, demonstrated significant efficacy. Patients receiving the 25 mg oral dose in conjunction with lifestyle modifications achieved a mean weight reduction of 17%, compared to a 3% reduction in the placebo arm. Notably, roughly one-third of the participants in the treatment group achieved weight loss of 20% or more.

This approval complements the existing Wegovy product portfolio, which currently includes once-weekly injectable formulations.

Industry Context

This regulatory advancement signals a broader trend toward the consumerization of chronic metabolic care. By eliminating the necessity of self-injection, the therapy is positioned to reach a wider patient demographic, specifically those with a psychological aversion to needles. This evolution moves high-potency metabolic agents into a traditional oral format, effectively decoupling clinical efficacy from complex, high-touch medical intervention.

For the broader pharmaceutical industry, this shift necessitates a change in operational focus. While oral delivery enhances patient convenience, it places the primary responsibility for adherence on the user. Moving forward, competitive positioning will likely transition away from delivery-method innovation toward the development of robust real-world evidence.

Industry stakeholders should also prepare for increased pressure on pharmacy-level inventory management and supply chain logistics as oral demand scales. Looking ahead, future industry differentiation will likely be driven by long-term maintenance data and comparative outcomes against a growing pipeline of oral metabolic therapies.